Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning and a warm welcome to Oriola. This is the Q3 2026 interim report audiocast. I am from Oriola Investor Relations. And joining me today are our CEO Katarina Gabrielsson and CFO Mats Danielsson. We will start with Katerina, who will take us through the quarter. And Mats will then cover the financials. After that, we'll open the Q&A. As a reminder, we will first focus on questions relating to Oriola business and financial performance. You are welcome to submit your questions through the chat at any point during the presentation. And just a practical note, we are recording today's audiocast, and the recording will be available on our website later today. Before we get started, a quick look at our customary disclaimer. And with that, Katerina, over to you.
Thank you, Tova. And also a warm welcome on my behalf. If you look at the third quarter, we had a solid business performance and we continued to strengthen our profitable growth. I will return later in this presentation to discuss how we achieved this, but specifically, the commercial execution, the operational improvements, and infrastructure development continued to strengthen our performance. Net sales grew by 5%, supported by continued high volumes, especially in specialty flows, sales growth in wholesale, and strong sales in special-licensed medicines. Last quarter, we talked a lot about higher fuel prices and also how we could pass costs through to our customers. This is something that we have succeeded with in the third quarter, and I'm really pleased to see that. But during the quarter, we also had a one-off inventory provision, and you will hear more about this in this presentation going forward. That was €0.7 million, and that has affected the group's profitability. So we landed on last year's level during the quarter. We also have stable supply chain operations. We have high volumes in our warehouses, to some extent depending on the geopolitical situation around us. That means we have high inventory levels and also capacity pressures. During the quarter, we also announced that we have revisited our implementation strategy for the ERP and warehouse management programme. That has been revised based on the insights from the first deployment that we did in Sweden at the end of last year. And now the timeline allows us parallel core builds and also direct deployment into Järvenpää. We will also come back to that a little bit later in this presentation. One highlight for this quarter is, of course, Kronans Apotek. We could see another quarter of growth and profitability improvements from Kronans Apotek. It has mainly been by disciplined focus on commercial performance and cost efficiency. And this is also based on the CMD discussions that we had earlier this year. And I know that Max will come back to the figures later on for Kronans Apotek. Moving to the operating environment at Oriola, we saw stable market shares in Finland and Sweden during the quarter. The pharmaceutical distribution market grew in Sweden by around 7%. Sweden showed growth of around 7%. Around 8%. While the growth in Finland remained low with only 0.5%. The geopolitical developments that I mentioned before, especially when it comes to fuel prices and inflationary pressures, are still present, and they contribute to an uncertain operating environment. Looking forward, we can see that pharmaceutical companies are building their inventories to some extent to ensure the availability of pharmaceuticals in our markets. In advisory services, the geopolitical development is continuing. Continuing also to have more cautious customer decision making, like we also mentioned earlier this year. This means longer lead times for new engagements. Consumer confidence in Finland and Sweden has been a little bit different in the two countries. Now during the third quarter in Finland, we can see that it is below the long-term average. While in Sweden in the end of the quarter, it has been rising sharply and is now in line with the historical average. Then if we go into the services segment, I will start. I will start with the service segment, which consists of the distribution of pharmaceuticals, the value-adding services, and parallel import in the Nordics. The segment we have here also includes Advisory Services and Commercial Data Solutions. Service segments had a net sales growth of 3.7% and landed on €36.4 million, and it has been supported especially by the volumes in the specialty flows, which include the export business, vaccines, and also animal health. We can also see solid development in direct pharmacy deliveries. The adjusted EBITDA improved and landed at €10.1 million, and the improved adjusted EBITDA was driven very much by this net sales growth. As I mentioned before, if you now look back to what we talked about in the CMD, we talked a lot in this segment about strengthening the customer and the joint account planning. And this is something that we can see. We have worked on this a lot during the quarter and also during the full year, and this is now also visible when we look at extended key partnerships and a healthy pipeline across the markets. We have now new key partnerships that will affect both the fourth quarter and the business from 2027. In advisory services, we can see that the sales have remained weak during the quarter. Basically, on the longer lead times in the decision-making from the pharmaceutical company, what we have worked on in our advisory business is to further strengthen our customer engagement and work more on integrated businesses. That is also done in all the different countries where we have advisory services; in Sweden, we launched an AI-enabled commercial data service, and that is something that has also been bought by pharmaceutical companies. This covers the medical information that we have. It takes the data we have in medical information and turns it into actionable product insights that are helping the pharmaceutical companies now in their decision-making. Then, if we continue with the product segment, the segment consists of the wholesale of traded goods and over-the-counter products, as well as our own brands and special-licensed medicines that we have in Finland and Sweden. And the segment also includes the dose dispensing business that we have in Finland. The net sales in this segment grew by 8.8% and landed at €16.8 million, driven especially by wholesale growth overall and strong sales of special-licensed medicines. That has been a part of this growth, as well as the dose dispensing business in Finland. I am also pleased to see that we have now started to sell to one new customer in Sweden. And that is a new specialty retail customer that we have brought into our customer pipeline. The adjusted EBITDA was slightly lower than last year. It landed at €1.7 million. The reason for this is this one-off product inventory provision of €0.7 million that I mentioned earlier. That is then affecting this segment negatively. If you then look here at what we discussed at the CMD, we also talked about how we work with the customer, as well as how we work with the product portfolio. In this segment, we have now continued to align the product portfolio and also take the products to the growing sales channels. And that is something that we can see in the results, especially in the sales. We will continue now to develop our own brands, as we have also done during the quarter. And that includes both how we price the products, how we do the offering to the customers, and also how we strengthen the competitiveness in these product groups compared to our other competitors. We continue to see that the recent launches have been well received and have gained new listings with our customers. Normally, we talk quite a lot about the big investments that we do at Oriola. I would now like to take the opportunity to talk about the continuous improvements that we, in fact, make every day in our business. And we will today focus a little bit here on what we do in the supply chain and the efficiency that we drive here. Supply chain is one of the biggest costs, of course, that we have in Oriola. It is crucial that we work on continuous improvements every day. As I mentioned before, we also have higher volumes in our warehouses. And that is, of course, increasing the capacity pressure that we have in our warehouses. What we do then to balance these volumes is, of course, to use external warehousing. And this is something that we work with to maximize the net income and the profitability that we have, and also how to handle new customers and growing stock levels. On top of this, we work a lot with transportation, which is one of the major cost elements that we have in Oriola. And it is, of course, crucial to work with route planning and delivery accuracy, as well as streamline the tools in the sorting processes and focus on route optimization. Here we would like to mention the route optimization in northern Sweden. If you look at the map, you can see that northern Sweden does not have many inhabitants, but there are a lot of roads and many kilometers between different cities. So this is also a way of taking down the cost of transportation. AI and digital tools are something that we have mentioned frequently when it comes to our advisory business. But this is also something that we use in distribution or our operations. So here in our supply chain, we are working with digital tools and AI, for example, to use in inventory planning. This means that we can have the right product in the right volumes at the right sites to be able to maintain high picking accuracy for our customers. And also that we release the working capital in our balance sheet. But with this, we will then turn to what we normally discuss. And those are the strategic projects that we are working on. And what we talked about in the CMD is that we should double the adjusted EBITDA by 2029 and strengthen the foundation for our future growth, and that this strategic project is a vital part of reaching that goal. During the quarter, we have revised and updated the timeline for the ERP and warehouse management programme. I can assure you that this has not changed and that we still have the goal to double the adjusted EBITDA by 2029. It is still there. What we have revised now in the ERP and warehouse management programme is that we have taken the learnings from the first deployment and implemented a new strategy and programme based on that, while also ensuring the Järvenpää distribution centre is included at the end of this period, and we have strengthened the programme and the programme governance. We are taking more ownership into our own business. So the internal organization has been strengthened, taking more ownership of the total programme. We have also appointed a new implementation partner in this process. The revised timeline has been extended to 2028 to be balanced with the Järvenpää distribution centre, and we will take a direct deployment into the distribution centre. The investment has now been revised and landed on €54 million, whereas it was previously €35 million. But this enables us now a parallel core build in Sweden and in Finland. This is followed by the phased implementation of our ERP and warehouse management programme as mentioned earlier. Of course, we are also doing some, in this scope, smaller projects with the warehouse automation upgrade. This is something that is very crucial for Sweden, where we can see that we will have the possibility in the first quarter next year to get more volumes through Enköping automation, and that will support the growth in the business in both distribution and wholesale. And I will also mention here that the Järvenpää distribution centre is continuing to advance according to the schedule. And with this, I conclude. That concludes the business highlights, and I will now leave the floor to Måns.
Thank you Katarina, and welcome. Also from my side, we can start by talking about our net sales. We had a 5.1% increase in net sales this quarter. The graph in the middle top shows that this was driven by both the product segment and the services segment. Percentage-wise, the product segment was growing more, but the service segment was also delivering good growth in both segments in euros. Invoicing for the quarter was plus 3.4%. If we look at the net sales for the year-to-date for the three quarters, we are at plus 1.6%. If we then eliminate the Swedish dose dispensing business that we still had in Q1 2025, the growth is 4.1%. Looking at the performance year to date. So far this year, we have had a good performance. As Katerina mentioned, we have had good growth in the distribution segment and the services segment. The distribution part. We have had specialty flows like export and vaccines, and we have also had good sales of value-added services. On the product side, there has been good development in the wholesale part, special-licensed medicines, and also dose dispensing; all areas in the product segment have been growing fairly well, especially in the third quarter. And invoicing for year-to-date is plus 5.6%. Then if we look at the adjusted EBITDA, we are on the quarter on the same level as last year. This includes the inventory provisions of -0.7 million euros coming from the special-licensed medicines. It is a one-off booking that we have. But we are on the same level. If we look at the margin for the quarter, we are at 18.1% compared to 19%. If we adjust the quarter with the provision, we would have been at 19.4% compared to 19%. So, an improvement on that side. If you look at the year to date, we are slightly higher than last year. Of course, this is now impacted also by the provision. As you might remember, we also had an increased freight cost due to fuel in the second quarter. On a high level, if these two items are eliminated, we are showing a margin percentage that is close to 17% compared to 16.1% last year. So, the underlying EBITDA margin is growing compared to last year. Then if we go into the services segment, we have had a bit of lower growth in the invoicing from our customers. However, the net sales have improved, especially in the third quarter. This is much related to what was commented earlier. It is export, vaccine, and animal health growing. And we have also included under net sales the service fees for the value-added services that we sell. And then we have had in the quarter also some increased partnerships in Finland that have supported the growth, although Advisory's net sales is continuously lower than last year, affecting the development a bit negatively. If we look at the adjusted EBITDA, we had a good quarter, with good net sales growth and also an improved EBITDA from 9.6 million to 10.1 million. Then year-to-date, we are behind last year, but still getting closer to last year. And, of course, especially in the services segment, the increase in fuel prices during the quarter is affecting the EBITDA number. Then if we go to the product segment, this was a good quarter in all areas. We had good sales in the wholesale part, and the dose dispensing part was also good. Special-licensed medicines performed well. So a really good development with 8.8% growth, while year-to-date we are at -3%. But if we eliminate the dose dispensing business in Sweden, the net sales grew by 4.6 percent. Looking at the adjusted EBITDA, we can see that the EBITDA is slightly lower than last year. But here, we have included the inventory provision. And if we look at the year-to-date adjusted EBITDA, we are improving despite this inventory provision that we have had. And if we look at the EBITDA percentage margin, excluding the dose dispensing, we are at 9.8% compared to 8.4%. And if we also exclude the provision from the numbers, we are actually above 11% compared to 8.4% last year. So an underlying improvement in the product segment. And if we look at the year-to-date net profit, we take out one part here and look at the share of the result of Kronans Apotek. That is improving, of course, compared to last year, which is a positive development for us. We continue to perform well. We can also see that the profit for the period is actually 8 million higher than last year. Then if we look at the cash flow, two things here are the changes in working capital. We have reduced factoring as you can see from the numbers. Also, we had 122 million at the end of last year, and it is below 100 now. So it is more than 20 million affecting the cash flow. That is a one-time, one-off event, of course, reducing the factoring volumes with the customer. And then we have an invoicing mix of customer changes now during the autumn that has affected this. And then of course, the product segment is growing, which is also having a slight effect. And then we have some FX differences. So there are a few big things that are affecting this. At the same time, we know that reducing the factoring programme will reduce our interest expenses. Despite the increased interest rates, we have also reduced our interest expenses in the quarter, with investments at 8.5 million compared to 1.8 million last year. We have now acquired the Järvenpää land area as part of this investment. And then we have the automation part in Enköping that is also an investment. So negative 29.8 million in free cash flow compared to plus 11.6 million last year. If we look at the net debt, it is fairly on the same level as last year for the same period and has not changed from quarter two. Here we can also see the big difference in the sold receivables, 99.6 compared to 109 last year in September. And it is also good to remember that it was 122 at the end of last year. Financial position remains stable with no significant changes in gearing or equity ratio. It is at the same level as the previous quarter. And then we can go in and look at Kronans Apotek. I would say that this is now the result of no longer working with the integration. You can see that the company is working with the right things. It is a big commercial focus looking at the pharmacies, opening hours, efficiencies in pharmacies, campaigns, and how can we sell additional products? And on the other hand, there has been an organizational restructuring looking at the head office, but also the working hours in the pharmacies; if we look at the adjusted EBITDA, we are quite close to last year's level. But if you then look at the EBIT for the quarter, there is a big difference. And that, of course, gives an impact on the results for the period and for the quarter as well. And especially if we look at the same numbers for year-to-date, we can see that the integration costs were much higher last year compared to this year. And therefore, we have almost a 5 million difference in the net result for the year-to-date, which of course has a big impact on our numbers also. That concludes the section. The outlook remains unchanged. Yes. The outlook is unchanged. For the full year, we aim to increase the adjusted EBITDA from 35.1 million.
Yes. And then I will conclude with the key takeaways. If you look at this, you can say that net sales grew by 5.1%, and both segments grew in net sales. We can see that the profitability has been resilient despite the challenges. We have this one-off inventory adjustment that you have heard a lot about during this audiocast. We have also had the possibility to pass through the higher fuel prices to our customers. We can also see that customer partnerships have been extended and new ones have been secured. That will be positive both for the end of this year, but also next year. In wholesale, we focus on growth channels and products that support profitable growth. We are also continuing with efficiency initiatives, both regarding larger investments and how they are improving, as well as the smaller ones we implement every day. And this has generated savings and improved the productivity and profitability. Of course, we are now building the foundation for growth; the ERP and WMS programs, and also the Järvenpää distribution centre, remain the key enablers for our modernization to reach double-digit profitability by 2029. And as Matt just said, here we are reiterating the outlook. We can see that the sales growth is expected to continue across both segments. And that is supported by a strong commercial momentum that we see now in the market. And also the new distribution partnerships that we have are set to contribute positively. Already in the fourth quarter, they will contribute, and efficiency gain actions will offset higher fuel costs and support profitability through continued cost discipline. And also, that is one of the reasons why we are reiterating now the outlook for the year. And with that, I think we conclude the presentation.
Yes. Thank you. So, thank you, Caterina, for talking us through the quarter. We will now turn to your questions, and you can continue to submit them through the chat. As a reminder, we will focus first on questions relating to Oriola's business and financial performance. We already have quite a few questions, and I will do my best to group them by topic. There are many questions relating to the ERP. So I will take those first and then continue with the other ones. Will the new ERP and WMS be live before Järvenpää starts operations in Q1 2028? If not, will you delay the move or open the Järvenpää distribution centre on the current system?
As we have mentioned, there will be phases in this implementation. In Sweden, the plan is to go live before Finland. In that aspect, yes, it will be live before we go to Järvenpää. But the plan here is to take the new system directly into use when we go live in Finland.
Good. Thank you. And of the roughly €29 million of ERP costs still to come, how much will be booked in 2027?
We will book about 5 million this year. It will be 15 million this year. It will be around 15 million next year, and then the rest will be a bit less than 10 million. The last in 2028.
And then a follow-up. Could you describe the possibilities that the ERP system will now have concerning the business efficiency and competitiveness of Oriola compared to if Oriola had continued according to the first deployment in Sweden?
I would say it is like this: efficiency-wise, it is not what we have changed in the program. The program is based on looking at our processes, how we work, and so on. And that is still the same part of the scope. What we changed now is how we do the implementation, how we set up the program to take away risks in the total program part and be able to launch it in the phases where we believe it is the best for the company. And it is still, as I said before, the platform and the part here are crucial for the business going forward. And it is also very important for the total business plan and strategy that we have from 2028 onwards and the 2029 result. Okay.
And could you comment whether Oriola will claim compensation from HCLTech for the ERP project? If compensation is received, will it be handled as an adjusting item? I would just comment that this was the previous partner implementation. Yes.
We are not commenting on the contract and the specifics of how we handle that. And of course, if there will be something, you will see that in the numbers.
Good. So those were the questions at the moment that were related to the ERP program. So let's continue now with the other questions. So, first, about the other services segment. Services EBITDA grew again despite advisory remaining weak. How should we think about the margin trajectory here going forward?
Yeah. We see that the growth was good in quarter three. And we expect that to grow and to achieve the full year numbers. We need growth and profitability in that segment.
What we can also see in the service segment is that, as we mentioned, we have more customers. We have onboarded customers in quarter three. And that will affect quarter four in a positive way. And we have also worked on the profitability of each customer. So that is part of the guidance, but also what we can see in this segment.
All right. So then, a question relating to the product segment. So what drove the underlying clear adjusted EBITDA improvement in products, and how repeatable is that?
I will say that it is repeatable because if you look at this, it is a lot about growth. It is net sales growth that we have in the main part of the businesses. And that has affected the adjusted EBITDA in a positive way. And what we have done now is, as I said, work with the basic parts of this segment. So when we are working with the products, we get new launches and so on. That will also affect earnings going forward.
Okay, good. Then, a couple of questions related to the rest of the year. So Q4 and guidance. Can you walk us through the key building blocks? How will you improve in Q4?
Overall, it is of course continued. And with the net sales growth and also the profitable growth that we have seen during Q3, we will continue to build on that. We can also see that the new distribution partnerships that we just mentioned will contribute positively already in the fourth quarter. So that's one part. And then we are working a lot with costs and efficiency gains to offset the high fuel costs, both with the continuous improvements that we mentioned here before, but also on the daily cost control that we have overall. So there are a lot of small things, but we are continuing what we did in the third quarter and improving from that.
Great. Thank you. And then a question related to the fuel prices. So the fuel prices have increased again in the fall. Should we expect a negative impact in Q4 from that, as was seen in Q2?
I will say that we now have the contracts in place. I do not expect that the fourth quarter will be affected in a negative way, as we saw in the second and third quarters. Now we have worked on that. And that should remain as it is in quarter three. In quarter four. Sorry.
Okay, good. Those were all questions related to Oriola. We will now move on to questions about Kronans Apotek. Just a reminder to please submit your questions through the chat. There is always a slight delay before we see them. So that we can take them during the audiocast. So the first question now is Kronans Apotek has had a new chairman for two months. Could you comment on his thoughts concerning the plus €60 million adjusted EBITDA target for Kronans Apotek by 2029 presented in the CMD? Is this doable according to him, or can we expect that this target is going to be changed?
Of course, I am not. I am not Magnus Håkanson. Of course, he should normally comment on this himself, but I know that both he and the full board, including the management, are committed to what we presented in the CMD. There is no change on that, even though we have made some changes in the board composition. So the targets, as well as the actions and goals that we presented in the CMD, are absolutely still valid. Right.
And then Oriola presented in the CMD. The savings target is €20 million in Kronans Apotek by 2027. Could you comment on how much of this has been achieved by Q3, and how much of it can we expect to see in Q4?
A part of this, as you can see in the numbers, is included in the quarter. Now there will be more in Q4, and the rest of the program will be seen in the next year. The program is working well.
And then there is the final question. This is a little bit related to what you just said, but maybe could you elaborate a little bit? Kronans Apotek has improved. Now in Q2 and Q3, are the efficiency measures presented at the CMD working?
They are working. They are working in all the areas that we presented. Also, with personnel costs, driving the pharmacies, and the different activities they have around sales in the pharmacies is working, and they are focusing on that now that the integration has ended, giving them the time and energy to work on those areas instead of integrating the two companies and the systems.
Basic retail.
Basic retail improvements.
Good. Thank you. So that seems to be all the questions we have today. So thank you everyone for joining us today. If there's anything else you'd like to discuss with us, please feel free to get in touch afterwards. Thank you again and have a great rest of the week.



















